1. A randomized trial of anemia correction with two different hemoglobin targets in the first-line chemotherapy of advanced gastric cancer

   • Se Hoon Park
   • Eunmi Nam
   • Jae Hoon Lee

   Original Article 10 August 2007 Pages: 1 - 9

   

2. Sequential vinorelbine–capecitabine followed by docetaxel in advanced breast cancer: long-term results of a pilot phase II trial

   • Marwan Ghosn
   • Joseph Kattan
   • For the Cancer Research Group/Collaborative Group (CRG/CG), Beirut–Lebanon

   Original Article 24 August 2007 Pages: 11 - 18

   

3. Preclinical studies of treosulfan demonstrate potent activity in Ewing’s sarcoma

   • Sebastian Werner
   • Arnulfo Mendoza
   • Udo Kontny

   Original Article 01 September 2007 Pages: 19 - 31

   

4. Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis

   • Richard M. Logan
   • Rachel J. Gibson
   • Dorothy M. K. Keefe

   Original Article 17 August 2007 Pages: 33 - 41

   

5. Phase I study of vinorelbine and irinotecan in previously untreated patients with advanced non-small cell lung cancer

   • Nanae Tomonaga
   • Yoichi Nakamura
   • the Nagasaki Thoracic Oncology Group

   Original Article 24 August 2007 Pages: 43 - 49

6. In vitro evaluation of the effects of gefitinib on the modulation of cytotoxic activity of selected anticancer agents in a panel of human ovarian cancer cell lines

   • Judith A. Smith
   • Anjali Gaikwad
   • Clinton F. Stewart

   Original Article 12 September 2007 Pages: 51 - 58

   

7. A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein–Barr virus DNA as a biomarker of efficacy

   • Brigette Ma
   • Edwin P. Hui
   • Anthony T. C. Chan

   Original Article 29 August 2007 Pages: 59 - 64

   

8. Phase 2B trial of aminopterin in multiagent therapy for children with newly diagnosed acute lymphoblastic leukemia

   • Peter D. Cole
   • Richard A. Drachtman
   • Barton A. Kamen

   Original Article 02 September 2007 Pages: 65 - 75

   

9. A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma

   • Jeeyun Lee
   • Young-Hyuck Im
   • Young Mog Shim

   Original Article 31 August 2007 Pages: 77 - 84

   

10. Suppression of thymidine phosphorylase expression by promoter methylation in human cancer cells lacking enzyme activity

    • Vincenzo Guarcello
    • Carmelo Blanquicett
    • Mahmoud H. el Kouni

    Original Article 01 September 2007 Pages: 85 - 96

    

11. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety

    • Feng Guo
    • Stephen P. Letrent
    • Amarnath Sharma

    Original Article 06 September 2007 Pages: 97 - 109

    

12. Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells

    • Tadahiko Kubo
    • Shoji Shimose
    • Mitsuo Ochi

    Original Article 15 September 2007 Pages: 111 - 116

    

13. Mechanistic study of potentiation of chemotherapy by a haloenol lactone derivative in vitro

    • Wei Wang
    • Cindy Q. Xia
    • Jiang Zheng

    Original Article 25 September 2007 Pages: 117 - 122

    

14. Pharmacodynamic model for chemotherapy-induced anemia in rats

    • Sukyung Woo
    • Wojciech Krzyzanski
    • William J. Jusko

    Original Article 22 September 2007 Pages: 123 - 133

    

15. Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment

    • Gerald J. Fetterly
    • Joel S. Owen
    • Juan Jose Perez-Ruixo

    Original Article 09 October 2007 Pages: 135 - 147

    

16. Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer

    • Howard H. Bailey
    • Steven Attia
    • James A. Stewart

    Original Article 21 September 2007 Pages: 149 - 157

    

17. Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer

    • Tomo Osako
    • Yoshinori Ito
    • Kiyohiko Hatake

    Original Article 20 September 2007 Pages: 159 - 164

    

18. Bisphosphonates induce apoptosis in CLL cells independently of MDR phenotype

    • Karina Lani Silva
    • Deborah Vidal Vasconcellos
    • Raquel Ciuvalschi Maia

    Original Article 12 March 2008 Pages: 165 - 171

    

19. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer

    • J. Horti
    • E. Juhasz
    • I. Bodrogi

    Clinical Trial Report 23 January 2008 Pages: 173 - 180

    

20. Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome

    • C. S. Chim

    Letter to the Editor 31 August 2007 Pages: 181 - 182